BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

Trials & Programmes

STATUS

SETTINGS

SUBTYPES

Icon

Breast cancer in pregnancy (BIG 2-03)

Registry of women treated for breast cancer while pregnant

Icon

Male breast cancer (BIG 2-07)

Registration and biologic characterisation programme of breast cancer in men

Icon

DCIS (BIG 3-07)

Radiation doses and fractionation schedules for women with DCIS

Icon

SOLD (BIG 1-10)

Short (9 weeks) versus long (1 year) treatments of early HER2-positive breast cancer with trastuzumab

Icon

APHINITY (BIG 4-11)

Comparison of single-versus-dual anti-HER2 therapy (trastuzumab, pertuzumab) for patients with HER2-positive breast cancer

Icon

MA.17 (BIG 1-97)

Extended adjuvant endocrine therapy in hormone dependent breast cancer

Icon

IES (BIG 2-97)

Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

Icon

BIG 1-98

Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor positive tumours

Icon

TAX (BIG 2-98)

Docetaxel in different regimens in the adjuvant treatment of node-positive breast cancer patients

Icon

p53 (BIG 1-00)

p53 gene analysis in women with large operable or locally advanced or inflammatory breast cancer

Icon

HERA (BIG 1-01)

Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer

Icon

SOFT (BIG 2-02)

Evaluation of ovarian suppression and of exemestane for premenopausal women with endocrine responsive breast cancer

Icon

TEXT (BIG 3-02)

Evaluation of exemestane plus GnRH analogue for premenopausal women with endocrine responsive breast cancer

Icon

IBIS-II (BIG 5-02)

Prevention study of anastrozole for postmenopausal women at increased risk of breast cancer; and of effects of tamoxifen vs. anastrozole in postmenopausal women with DCIS

Icon

REACT (BIG 1-03)

Trial of celecoxib for patients with primary breast cancer

Icon

AZURE (BIG 1-04)

Adjuvant zoledronic acid for patients with high-risk, localised breast cancer

Icon

SUPREMO (BIG 2-04)

Adjuvant chest wall irradiation for ‘intermediate risk’ breast cancer following mastectomy

Icon

MINDACT (BIG 3-04)

Can addition of 70-gene signature to common clinical-pathological criteria safely spare patients from adjuvant chemotherapy?

Icon

ICE (BIG 4-04)

Ibandronate with or without capecitabine for elderly patients with early breast cancer

Icon

BIG 2-05 ACTION

The Adjuvant cytotoxic ChemoTherapy in older womeN (ACTION) study is a randomised trial of chemotherapy in older women.

Icon

Neo-ALTTO (BIG 1-06)

Comparison of dual HER2 inhibition (lapatinib, trastuzmab) plus chemotherapy before surgery versus single HER2-targeted therapy

Icon

ALTTO (BIG 2-06)

Adjuvant lapatinib and trastuzumab: sequence and combination for patients with HER2/ErbB2 positive primary breast cancer

Icon

SOLE (BIG 1-07)

Continuous versus intermittent letrozole following endocrine treatment for postmenopausal women disease-free of hormone-receptor-positive, node-positive breast cancer

Icon

FINESSE (BIG 2-13)

Oral lucitanib for patients with FGFR1 ER+ metastatic breast cancer

Icon

TREAT CTC (BIG 1-12)

TRastuzumab treatment for HER2-negative early breast cancer in the presence of circulating tumor cells

Icon

SNAP (BIG 2-12)

Evaluation of different schedules of nab-paclitaxel for metastatic breast cancer

Icon

PENELOPE-B (BIG 1-13)

Post-neoadjuvant palbociclib for patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk

Icon

NeoPHOEBE (BIG 6-11)

Buparlisib for HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer

Icon

BRAVO (BIG 5-13)

Niraparib for patients with HER2-negative, germline BRCA mutation-positive breast cancer

Icon

OlympiA (BIG 6-13)

Olaparib for patients with BRCA-mutated, high-risk HER2-negative breast cancer

Icon

MA.32 Metformin (BIG 5-11)

Effect of metformin on recurrence and survival in early stage breast cancer

Icon

Young Patients Fertility Survey (BIG 3-98)

Attitudes of patients under age35 with early breast cancer towards the risk of loss of fertility

Icon

PANACEA (BIG 4-13)

Evaluating the efficacy of MK-3475, an anti-PD-1 monoclonal antibody, and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers

Icon

POSITIVE (public name: BIG Time for Baby)

Endocrine therapy interruption to enable conception for young women with ER+ breast cancer

Icon

AURORA (Metastatic Breast Cancer GPS)

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240